(Q35333643)

English

Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Cytomegalovirus

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

F Aweeka

1

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

J Gambertoglio

2

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

J Mills

3

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

M A Jacobson

4

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

language of work or name

0 references

publication date

1 May 1989

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

742-745

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Treatment of cytomegalovirus pneumonitis with foscarnet (trisodium phosphonoformate) in patients with AIDS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=172525

12 July 2018

Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=172525

12 July 2018

Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=172525

12 July 2018

Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=172525

12 July 2018

The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=172525

12 July 2018

Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=172525

12 July 2018

Acute renal failure induced by foscarnet: 4 cases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=172525

12 July 2018

Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=172525

12 July 2018

Inhibition of HTLV-III/LAV replication by foscarnet

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=172525

12 July 2018

Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=172525

12 July 2018

Prediction of creatinine clearance from serum creatinine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=172525

12 July 2018

Antiviral effects of phosphonoformate (PFA, foscarnet sodium)

1 reference

https://pubmed.ncbi.nlm.nih.gov/2546491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (Foscarnet)

1 reference

https://pubmed.ncbi.nlm.nih.gov/2546491

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.33.5.742

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35333643&oldid=1576316324"